Hospital-wide Implementation of Masimo Rainbow SET(R) Pulse
CO-Oximetry(TM) Could Generate Nearly $500,000 in Net Annual Cost Savings and
Financial Gains
IRVINE, Calif., April 16, Masimo (Nasdaq: MASI), the inventor of Pulse
CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry,
announced today that Capgemini, a leading supplier of global consulting and
technology services, has released a study showing that a typical 500 bed
hospital incorporating Masimo Rainbow SET Pulse CO-Oximetry into its clinical
standards and care pathways could generate nearly $500,000 in net annual cost
savings and financial gains.
Capgemini reported that significant financial benefits could be derived
from incorporating noninvasive total hemoglobin (SpHb) by helping clinicians
prevent unnecessary blood transfusions, identify internal bleeding earlier,
and increase patient throughput. The study concluded that "whether considered
on a per-patient, department, or hospital-wide analysis, there are significant
clinical and financial benefits to implementing Pulse CO-Oximetry technology."
Masimo commissioned the Capgemini study for a third-party evaluation of
the potential financial benefits of Masimo Rainbow SET. Hospital inputs were
evaluated by Capgemini through 70 in-depth one-on-one interviews with
clinicians and other decision-makers at 15 U.S. acute care hospitals and then
quantified through a follow-on survey of 200 hospital-based physicians. The
study found that the majority of anesthesiologists and two-thirds of surgeons
believed that SpHb monitoring could prevent at least one unnecessary blood
transfusion in every ten surgical cases on which it was used, contributing to
$93,600 in net annual cost savings in a surgical department using 20
SpHb-enabled devices. The study also found that the majority of intensivists
believed that SpHb monitoring could reduce intensive care length of stay by at
least one day for every 15 or fewer patients on which it was used,
contributing to $67,350 in net annual cost savings in an intensive care
department using 10 SpHb-enabled devices.
Joe Kiani, Founder and CEO of Masimo, stated, "We believe that the
Capgemini study will significantly aid hospitals seeking to evaluate the
initial and ongoing investment in Masimo Rainbow SET by clearly identifying
each of the various mechanisms by which SpHb can improve the clinical process
of care and create net financial benefits."
The Capgemini study can be downloaded at www.masimo.com/capgemini. In
addition, a customized financial analysis based on a hospital's own inputs
incorporated into the Capgemini financial model is available upon request.
About Masimo
Masimo (NASDAQ: MASI) develops innovative monitoring technologies that
significantly improve patient care-helping solve "unsolvable" problems. In
1995, the company debuted Measure-Through Motion and Low-Perfusion pulse
oximetry, known as Masimo SET(R), which virtually eliminated false alarms and
increased pulse oximetry's ability to detect life-threatening events. More
than 100 independent and objective studies demonstrate Masimo SET provides the
most reliable SpO2 and pulse rate measurements even under the most challenging
clinical conditions, including patient motion and low peripheral perfusion.
In 2005, Masimo introduced Masimo Rainbow SET(R) Pulse CO-Oximetry(TM), a
breakthrough noninvasive blood constituent monitoring platform that can
measure many blood constituents that previously required invasive procedures.
Masimo Rainbow SET continuously and noninvasively measures total hemoglobin
(SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO(R)),
methemoglobin (SpMet(R)), and PVI(TM), in addition to oxyhemoglobin (SpO2),
pulse rate (PR), and perfusion index (PI), allowing early detection and
treatment of potentially life-threatening conditions. Founded in 1989, Masimo
has the mission of "Improving Patient Outcomes and Reducing Cost of Care by
Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, in connection with the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are based on current
expectations about future events affecting us and are subject to risks and
uncertainties, all of which are difficult to predict and many of which are
beyond our control and could cause our actual results to differ materially and
adversely from those expressed in our forward-looking statements as a result
of various risk factors, including, but not limited to: risks related to our
assumptions regarding the accuracy and repeatability of the Capgemini
financial model and results; risks related to our belief that the applications
of Masimo Rainbow SET measurements described in the foregoing statements will
deliver a sufficient level of clinical improvement over alternative
measurement capabilities to create substantial financial benefits for
hospitals, allow for rapid adoption of the technology, and materially increase
market share and/or revenues for the company, as well as other factors
discussed in the "Risk Factors" section of our Annual Report on Form 10-K for
the fiscal year ended January 3, 2009, filed with the Securities and Exchange
Commission ("SEC") on March 4, 2009, which may be obtained for free at the
SEC's website at www.sec.gov. Although we believe that the expectations
reflected in our forward-looking statements are reasonable, we do not know
whether our expectations will prove correct. All forward-looking statements
included in this press release are expressly qualified in their entirety by
the foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of today's
date. We do not undertake any obligation to update, amend or clarify these
forward-looking statements or the "Risk Factors" contained in our Quarterly
Report on Form 10-Q for the fiscal year ended January 3, 2009, whether as a
result of new information, future events or otherwise, except as may be
required under the applicable securities laws.
Contact:
Dana Banks
Masimo Corporation
949-297-7348
Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing
Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications,
Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87, Rad-57, Rad-9,
Rad-8, Rad-5, Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or
registered trademarks of Masimo Corporation. Other trademarks used herein are
the property of their respective owners.
SOURCE Masimo Corporation
Web Site: http://www.masimo.com